Novel Compound Heterozygous ZAP70 R37G A507T Mutations in Infant with Severe Immunodeficiency
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-023-01608-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Nathalia Benavides und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes, Severe Combined Immunodeficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Zeta-chain associated protein kinase 70 kDa (ZAP70) combined immunodeficiency (CID) is an autosomal recessive severe immunodeficiency that is characterized by abnormal T-cell receptor signaling. Children with the disorder typically present during the first year of life with diarrhea, failure to thrive, and recurrent bacterial, viral, or opportunistic infections. To date, the only potential cure is hematopoietic stem cell transplant (HSCT). The majority of described mutations causing disease occur in the homozygous state, though heterozygotes are reported without a clear understanding as to how the individual mutations interact to cause disease. This case describes an infant with novel ZAP-70 deficiency mutations involving the SH2 and kinase domains cured with allogeneic HSCT utilizing a reduced-intensity conditioning regimen and graft manipulation. We then were able to further elucidate the molecular signaling alterations imparted by these mutations that lead to altered immune function. In order to examine the effect of these novel compound ZAP70 heterozygous mutations on T cells, Jurkat CD4+ T cells were transfected with either wild type, or with individual ZAP70 R37G and A507T mutant constructs. Downstream TCR signaling events and protein localization results link these novel mutations to the expected immunological outcome as seen in the patient's primary cells. This study further characterizes mutations in the ZAP70 gene as combined immunodeficiency and the clinical phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA.
- Department of Pediatric Hematology/Oncology, Nemours Children's Hospital Delaware, Wilmington, USA.
- Department of Genetics, Nemours Children's Hospital Delaware, Wilmington, USA.
- Department of Allergy/Immunology, Nemours Children's Hospital Delaware, Wilmington, USA.
- Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA. Claudio.Giraudo@jefferson.edu.
ORCID-Profile: Claudio G Giraudo
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Benavides, N., White, J. C., Sanmillan, M. L., Thomas, M., Le, T., Caywood, E., & Giraudo, C. G. (2024). Novel Compound Heterozygous ZAP70 R37G A507T Mutations in Infant with Severe Immunodeficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-023-01608-2
Vancouver
Benavides N, White JC, Sanmillan ML, Thomas M, Le T, Caywood E, et al. Novel Compound Heterozygous ZAP70 R37G A507T Mutations in Infant with Severe Immunodeficiency. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-023-01608-2
BibTeX
@article{Benavides2024,
author = {Benavides, Nathalia and White, Jason C and Sanmillan, Maria L and Thomas, Morgan and Le, Trong and Caywood, Emi and Giraudo, Claudio G},
title = {Novel Compound Heterozygous ZAP70 R37G A507T Mutations in Infant with Severe Immunodeficiency},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-023-01608-2}
}
EUVIMED